Anthem Biosciences
Anthem Biosciences Share Price Chart
Anthem Biosciences last traded at ₹885.40 (2026-10-13). Over the past month the stock moved -6.0%, three months the stock moved +14.7%, year the stock moved +12.8%. Its closing range over 52 weeks is ₹587.85 – ₹959.00, with the latest close 7.7% below the high.
Closing prices up to 2026-10-13.
About Anthem Biosciences
Incorporated in 2006, Anthem Biosciences Ltd is in the business of providing CRDMO services and the manufacture and sale of specialty ingredients.[1]
Business Overview:[1] ABL is a Contract Research, Development, and Manufacturing Organization with fully integrated operations across the drug discovery, development, and manufacturing value chain. It is among the few companies in India offering capabilities in both New Chemical Entity (NCE) and New Biological Entity (NBE) programs. The company has developed various platforms such as RNA interference (RNAi), Antibody-Drug Conjugates (ADCs), peptides, lipids, and oligonucleotides.
Fundamentals
Quarterly Results
In the latest quarter (Jun 2026), Anthem Biosciences reported sales of ₹418.00 crore (-22.6%) and net profit of ₹120.00 crore (-11.8%), compared with the same quarter last year.
| Period | Sales | Operating profit | OPM % | Net profit | EPS (₹) |
|---|---|---|---|---|---|
| Jun 2026 | 418.00 | 151.00 | 36.00 | 120.00 | 2.13 |
| Mar 2026 | 611.00 | 267.00 | 44.00 | 190.00 | 3.38 |
| Dec 2025 | 423.00 | 157.00 | 37.00 | 93.00 | 1.65 |
| Sep 2025 | 550.00 | 218.00 | 40.00 | 173.00 | 3.09 |
| Jun 2025 | 540.00 | 191.00 | 35.00 | 136.00 | 2.42 |
| Mar 2025 | 483.00 | 195.00 | 40.00 | 83.00 | 1.48 |
| Dec 2024 | 498.00 | 160.00 | 32.00 | 124.00 | 2.22 |
| Sep 2024 | 525.00 | 195.00 | 37.00 | 162.00 | 2.90 |
| Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 | |
|---|---|---|---|---|---|
| Sales growth | +59.3% | +4.8% | -15.1% | +26.5% | -22.6% |
| Operating profit growth | +57.9% | +11.8% | -1.9% | +36.9% | -20.9% |
| Net profit growth | +65.9% | +6.8% | -25.0% | +128.9% | -11.8% |
| EPS growth | +64.6% | +6.6% | -25.7% | +128.4% | -12.0% |
| OPM % | 35.0% | 40.0% | 37.0% | 44.0% | 36.0% |
Colour scale: below -5% -5% to 0% 0% to 5% 5% to 20% 20% and above. A dash means the earlier figure was zero or negative, so a percentage is not meaningful.
Annual Financials
In the latest year (Mar 2026), Anthem Biosciences reported sales of ₹2,124.00 crore (+15.1%) and net profit of ₹592.00 crore (+31.3%), compared with the previous year.
| Period | Sales | Operating profit | OPM % | Net profit | EPS (₹) |
|---|---|---|---|---|---|
| Mar 2026 | 2,124 | 834.00 | 39.00 | 592.00 | 10.54 |
| Mar 2025 | 1,845 | 672.00 | 36.00 | 451.00 | 8.07 |
| Mar 2024 | 1,419 | 506.00 | 36.00 | 367.00 | 6.57 |
| Mar 2023 | 1,057 | 431.00 | 41.00 | 385.00 | 6.75 |
| Mar 2022 | 1,231 | 565.00 | 46.00 | 406.00 | 462.09 |
| Mar 2021 | 1,103 | 408.00 | 37.00 | 271.00 | 319.74 |
| Mar 2020 | 633.00 | 182.00 | 29.00 | 93.00 | 110.62 |
| Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|---|---|---|
| Sales growth | +74.2% | +11.6% | -14.1% | +34.2% | +30.0% | +15.1% |
| Operating profit growth | +124.2% | +38.5% | -23.7% | +17.4% | +32.8% | +24.1% |
| Net profit growth | +191.4% | +49.8% | -5.2% | -4.7% | +22.9% | +31.3% |
| EPS growth | +189.0% | +44.5% | -98.5% | -2.7% | +22.8% | +30.6% |
| OPM % | 37.0% | 46.0% | 41.0% | 36.0% | 36.0% | 39.0% |
Colour scale: below -5% -5% to 0% 0% to 5% 5% to 20% 20% and above. A dash means the earlier figure was zero or negative, so a percentage is not meaningful.
Shareholding
AI Analysis
No AI analysis generated yet for Anthem Biosciences.
Get Free AI Stock Analysis FREE →Latest News
-
Anthem Biosciences reports Profit after tax of Rs 1020.10 Mln, in the June 2026 quarter
-
Anthem Biosciences consolidated net profit declines 11.67% in the June 2026 quarter - Business Standard
-
Anthem Biosciences consolidated net profit declines 11.67% in the June 2026 quarter - Business Standard
-
Anthem Biosciences shares change hands as Societe Generale, Prudential, among others, buy 3% stake
-
Societe General, Prudential, others buy 3% stake in Anthem Biosciences for ₹1,275 cr - BusinessLine
-
Anthem Biosciences shares change hands as Societe Generale, Prudential, among others, buy 3% stake
-
Societe General, Prudential, Others Buy 3 PC Stake in Anthem Biosciences for Rs 1,275 Cr
-
Anthem Biosciences Schedules Board Meeting on May 19, 2026 to Approve FY26 Financial Results and Consider Final Dividend - scanx.trade
-
Anthem BioSciences shares jump 4% as Citi initiates with Buy rating. Check target, upside potential
-
Anthem Biosciences Ltd. - Moneycontrol.com
Frequently Asked Questions
What is the share price of Anthem Biosciences today?
Anthem Biosciences shares were last quoted at ₹885.40 (+2.7% on the day). Use the Refresh price button on this page for the latest available price. Prices are for information only.
What is the P/E ratio of Anthem Biosciences?
Anthem Biosciences has a price-to-earnings (P/E) ratio of 85.47 and a price-to-book (P/B) ratio of 15.57. The industry P/E is 53.33.
What is the 52-week high and low of Anthem Biosciences?
The 52-week high of Anthem Biosciences is ₹977.00 and the 52-week low is ₹579.45.
What is the market cap of Anthem Biosciences?
The market capitalisation of Anthem Biosciences is about ₹49,242.96 crore.
How did Anthem Biosciences perform in its latest quarterly results?
In the latest quarter (Jun 2026), Anthem Biosciences reported sales of ₹418.00 crore (-22.6%) and net profit of ₹120.00 crore (-11.8%), compared with the same quarter last year.
Is Anthem Biosciences a good stock to buy?
This page is for information and is not investment advice. As per the data shown here, Anthem Biosciences has a 3-year ROE of 21.00%, 3-year profit growth of 21.00%. Review the fundamentals, quarterly results and AI analysis on StockSpin, and consult a SEBI-registered adviser before investing.
What is the promoter holding in Anthem Biosciences?
Promoters hold about 71.42% of Anthem Biosciences.
Which sector does Anthem Biosciences belong to?
Anthem Biosciences belongs to the Pharmaceuticals & Drugs sector.